Patents by Inventor Leo Yen-Cheng Lin

Leo Yen-Cheng Lin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230227547
    Abstract: The present invention provides a covalent conjugate. The conjugate includes an antibody or antibody derivative, at least two LL37-derived polypeptides, and a payload. The antibody or antibody derivative targets a cell that has phosphatidylserine in its outer leaflet. The payload includes: a small molecule cytotoxic drug of less than 3 kDa, or a plurality thereof; or a peptide or protein of less than 100 kDa. Uses and methods of using these covalent conjugates are also provided, related to enhancing delivery of the antibody/derivative or the payload, e.g. to enhance therapeutic or diagnostic effectiveness.
    Type: Application
    Filed: November 12, 2019
    Publication date: July 20, 2023
    Applicant: IPROGEN BIOTECH INC.
    Inventors: Keun Ho Lee, Leo Yen-Cheng Lin, Ranjani Vaidyanathan, Paula Lario
  • Patent number: 10131888
    Abstract: A secretion signal peptide sequence (SP) in combination with a cleavage inhibition sequence (CIS) fused to a structural gene sequence in a recombinant expression system can be used to express a full length protein with an SP in a cell. Such a fusion protein may be purified to homogeneity from a membrane fraction of the cell. The SP in combination with the CIS is a protein transduction domain that exhibits superior intracellular protein transduction efficiency when the SP precedes the CIS in a N to C-terminus direction.
    Type: Grant
    Filed: May 3, 2018
    Date of Patent: November 20, 2018
    Assignee: IPROGEN BIOTECH INC.
    Inventors: Keun Ho Lee, Leo Yen-Cheng Lin, Aikun Wang
  • Publication number: 20180298359
    Abstract: A secretion signal peptide sequence (SP) in combination with a cleavage inhibition sequence (CIS) fused to a structural gene sequence in a recombinant expression system can be used to express a full length protein with an SP in a cell. Such a fusion protein may be purified to homogeneity from a membrane fraction of the cell. The SP in combination with the CIS is a protein transduction domain that exhibits superior intracellular protein transduction efficiency when the SP precedes the CIS in a N to C-terminus direction.
    Type: Application
    Filed: May 3, 2018
    Publication date: October 18, 2018
    Inventors: Keun Ho Lee, Leo Yen-Cheng Lin, Aikun Wang
  • Patent number: 9994829
    Abstract: A secretion signal peptide sequence (SP) in combination with a cleavage inhibition sequence (CIS) fused to a structural gene sequence in a recombinant expression system can be used to express a full length protein with an SP in a cell. Such a fusion protein may be purified to homogeneity from a membrane fraction of the cell. The SP in combination with the CIS is a protein transduction domain that exhibits superior intracellular protein transduction efficiency when the SP precedes the CIS in a N to C-terminus direction.
    Type: Grant
    Filed: July 2, 2013
    Date of Patent: June 12, 2018
    Assignee: IPROGEN BIOTECH, INC.
    Inventors: Keun Ho Lee, Leo Yen-Cheng Lin, Aikun Wang
  • Publication number: 20150191710
    Abstract: A secretion signal peptide sequence (SP) in combination with a cleavage inhibition sequence (CIS) fused to a structural gene sequence in a recombinant expression system can be used to express a full length protein with an SP in a cell. Such a fusion protein may be purified to homogeneity from a membrane fraction of the cell. The SP in combination with the CIS is a protein transduction domain that exhibits superior intracellular protein transduction efficiency when the SP precedes the CIS in a N to C-terminus direction.
    Type: Application
    Filed: July 2, 2013
    Publication date: July 9, 2015
    Inventors: Keun Ho Lee, Leo Yen-Cheng Lin, Aikun Wang